◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ANIP

ANI Pharmaceuticals Inc (ANIP) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-14

ANI Pharmaceuticals Inc (ANIP) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Baudette, United States with about 970 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ANIP reported $883M in revenue and $78M in net income.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.

Interactive charts & full statements → Open the ANIP valuation workbench →

ANIP Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$978M	$883M	$614M	$487M	$316M	$216M	$208M	$207M	$202M	$177M	$129M	$76M	$56M	$30M	$2M	$0M	$2M	$1M	$4M	$0M	$14M
Gross Profit	$639M	$451M	$364M	$305M	$178M	$116M	$121M	$143M	$129M	$98M	$80M	$64M	$44M	$20M	($7M)	$0M	$2M	$1M	$4M	$0M	$14M
Gross Margin %	65.3%	51.0%	59.3%	62.7%	56.1%	53.4%	58.2%	69.4%	63.8%	55.3%	62.1%	83.4%	79.5%	66.8%	-298.4%	88.5%	89.1%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$150M	$81M	$1M	$47M	($35M)	($40M)	($16M)	$16M	$35M	$28M	$20M	$33M	$20M	$1M	($23M)	($51M)	($44M)	($38M)	($18M)	($9M)	$3M
Operating Margin %	15.3%	9.2%	0.1%	9.7%	-11.2%	-18.4%	-7.7%	7.9%	17.5%	16.0%	15.6%	42.8%	35.7%	3.0%	-1007.1%	-11703.0%	-1762.5%	-3054.4%	-476.4%	-1760.3%	23.8%
Net Income	$105M	$78M	($19M)	$19M	($48M)	($43M)	($23M)	$6M	$15M	($1M)	$4M	$15M	$29M	$0M	($28M)	($52M)	($46M)	($48M)	($17M)	($8M)	$3M
Net Margin %	10.7%	8.9%	-3.0%	3.9%	-15.1%	-19.7%	-10.8%	2.9%	7.7%	-0.6%	3.1%	20.1%	51.4%	1.0%	-1204.7%	-11859.7%	-1867.1%	-3777.9%	-460.9%	-1538.3%	19.3%
EBITDA	$255M	$207M	$63M	$107M	$25M	$3M	$28M	$61M	$69M	$57M	$56M	$40M	$24M	$8M	($27M)	($51M)	($45M)	($47M)	($17M)	($7M)	$4M
Earnings Per Share (EPS)	$4.93	$3.69	$-0.96	$1.03	$-2.95	$-3.38	$-1.88	$0.51	$1.32	$-0.09	$0.34	$1.33	$2.60	$0.06	$-7.64	$-18.88	$-25.23	$-50.39	$-22.97	$-10.71	$3.00
Shares Outstanding (M)	22M	21M	19M	18M	16M	13M	12M	12M	12M	12M	12M	12M	11M	5M	4M	3M	2M	1M	1M	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANIP Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$266M	$237M	$247M	$228M	$211M	$197M	$191M	$148M
Gross Profit	$166M	$123M	$238M	$112M	$137M	$124M	$110M	$85M
Gross Margin %	62.4%	51.8%	96.2%	49.1%	64.7%	62.9%	57.9%	57.5%
Operating Income (EBIT)	$40M	$39M	$48M	$23M	$14M	$26M	($4M)	($21M)
Operating Margin %	15.2%	16.3%	19.5%	10.0%	6.6%	13.3%	-2.3%	-13.8%
Net Income	$25M	$29M	$27M	$24M	$9M	$16M	($10M)	($24M)
Net Margin %	9.3%	12.4%	11.1%	10.6%	4.0%	8.0%	-5.4%	-16.3%
EBITDA	$60M	$57M	$77M	$61M	$39M	$48M	$15M	($13M)
Earnings Per Share (EPS)	$1.13	$1.37	$1.29	$1.14	$0.42	$0.78	$-0.53	$-1.25
Shares Outstanding (M)	22M	22M	21M	21M	20M	20M	19M	19M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANIP Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$189M	$185M	$64M	$119M	($31M)	$3M	$15M	$46M	$67M	$39M	$27M	$17M	$22M	($5M)	($25M)	($48M)	($40M)	($18M)	($16M)	$1M	($5M)
Capital Expenditures (CapEx)	$52M	$34M	$17M	$19M	$16M	$24M	$68M	$28M	$11M	$108M	$149M	$33M	$36M	$0M	$1M	$1M	$0M	$0M	$1M	$0M	$0M
Free Cash Flow (FCF)	$137M	$151M	$47M	$100M	($48M)	($20M)	($53M)	$18M	$56M	($69M)	($122M)	($15M)	($14M)	($6M)	($26M)	($49M)	($40M)	($19M)	($16M)	$1M	($5M)
FCF Margin %	14.0%	17.1%	7.7%	20.6%	-15.1%	-9.4%	-25.4%	8.8%	27.9%	-38.8%	-94.5%	-20.2%	-24.5%	-18.9%	-1125.5%	-11166.0%	-1623.2%	-1478.2%	-428.1%	144.1%	-34.9%
Dividends Paid	$0M	$1M	$2M	$2M	$2M	$0M	$1M	$6M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANIP Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$57M	$58M	$30M	$44M	$76M	$35M	$16M	$12M
Capital Expenditures (CapEx)	$11M	$11M	$24M	$6M	$7M	$20M	$2M	$5M
Free Cash Flow (FCF)	$45M	$47M	$7M	$38M	$69M	$15M	$13M	$8M
FCF Margin %	17.0%	19.8%	2.6%	16.6%	32.6%	7.7%	7.0%	5.2%
Dividends Paid	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANIP Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.5B	$1.4B	$1.3B	$904M	$760M	$772M	$461M	$457M	$431M	$412M	$323M	$285M	$264M	$44M	$39M	$62M	$45M	$36M	$18M	$31M	$22M
Cash & Cash Equivalents	$360M	$286M	$145M	$221M	$48M	$100M	$8M	$62M	$43M	$31M	$27M	$155M	$169M	$11M	$35M	$57M	$38M	$30M	$12M	$16M	$8M
Total Liabilities	$897M	$900M	$855M	$447M	$422M	$413M	$265M	$244M	$233M	$237M	$153M	$125M	$124M	$4M	$11M	$25M	$26M	$21M	$4M	$2M	$4M
Total Debt (Short + Long-Term)	$610M	$617M	$624M	$286M	$287M	$287M	$186M	$186M	$183M	$132M	$241M	$227M	$217M	$1M	$8M	$17M	$1M	$0M	$0M	$1M	$0M
Total Shareholders' Equity	$597M	$541M	$429M	$458M	$339M	$359M	$196M	$213M	$197M	$175M	$170M	$160M	$140M	$41M	$28M	$38M	$19M	$16M	$14M	$30M	$18M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANIP viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

PBH · Prestige Brand Holdings Inc — $2 billion
BHC · Bausch Health Companies Inc — $2 billion
ALVO · Alvotech — $2 billion
PRGO · Perrigo Company PLC — $2 billion
ETON · Eton Pharmaceuticals Inc — $2 billion
XERS · Xeris Pharmaceuticals Inc — $1 billion
PAHC · Phibro Animal Health Corporation — $1 billion
HROW · Harrow Health Inc — $1 billion

← ANIKINDS All “A” companies ANIX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.